Literature DB >> 20018552

Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer.

Sergei I Grivennikov1, Michael Karin.   

Abstract

Transcriptional factors of the NF-kappaB family and STAT3 are ubiquitously expressed and control numerous physiological processes including development, differentiation, immunity, metabolism and cancer. Both NF-kappaB and STAT3 are rapidly activated in response to various stimuli including stresses and cytokines, although they are regulated by entirely different signaling mechanisms. Once activated, NF-kappaB and STAT3 control the expression of anti-apoptotic, pro-proliferative and immune response genes. Some of these genes overlap and require transcriptional cooperation between the two factors. The activation of and interaction between STAT3 and NF-kappaB plays a key role in controlling the dialog between the malignant cell and its microenvironment, especially with inflammatory/immune cells that infiltrate tumors. Quite often, cytokines whose expression is induced in response to NF-kappaB in immune cells of the tumor microenvironment lead to STAT3 activation in both malignant and immune cells. While within malignant and pre-malignant cells STAT3 exerts important oncogenic functions, within inflammatory cells it may also suppress tumor promotion through its anti-inflammatory effects. Other interactions and forms of crosstalk between NF-kappaB and STAT3 include physical interaction between the two, cooperation of these factors at gene promoters/enhancers, the NF-kappaB dependent expression of inhibitors of STAT3 activation and the participation of STAT3 in inflammatory cells in the negative regulation NF-kappaB. Despite these versatile and occasionally antagonistic interactions, NF-kappaB and STAT3 cooperate to promote the development and progression of colon, gastric and liver cancers. In addition to explaining the molecular pathogenesis of cancer, these interactions also offer opportunities for the design of new therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20018552      PMCID: PMC2834864          DOI: 10.1016/j.cytogfr.2009.11.005

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  112 in total

1.  Stat3 as an oncogene.

Authors:  J F Bromberg; M H Wrzeszczynska; G Devgan; Y Zhao; R G Pestell; C Albanese; J E Darnell
Journal:  Cell       Date:  1999-08-06       Impact factor: 41.582

2.  Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation.

Authors:  Z Wen; Z Zhong; J E Darnell
Journal:  Cell       Date:  1995-07-28       Impact factor: 41.582

3.  Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death.

Authors:  Z G Liu; H Hsu; D V Goeddel; M Karin
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

4.  A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB.

Authors:  J A DiDonato; M Hayakawa; D M Rothwarf; E Zandi; M Karin
Journal:  Nature       Date:  1997-08-07       Impact factor: 49.962

5.  Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality.

Authors:  K Takeda; K Noguchi; W Shi; T Tanaka; M Matsumoto; N Yoshida; T Kishimoto; S Akira
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

6.  Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses.

Authors:  D J Berg; N Davidson; R Kühn; W Müller; S Menon; G Holland; L Thompson-Snipes; M W Leach; D Rennick
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

7.  Suppression of TNF-alpha-induced apoptosis by NF-kappaB.

Authors:  D J Van Antwerp; S J Martin; T Kafri; D R Green; I M Verma
Journal:  Science       Date:  1996-11-01       Impact factor: 47.728

8.  An essential role for NF-kappaB in preventing TNF-alpha-induced cell death.

Authors:  A A Beg; D Baltimore
Journal:  Science       Date:  1996-11-01       Impact factor: 47.728

9.  TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB.

Authors:  C Y Wang; M W Mayo; A S Baldwin
Journal:  Science       Date:  1996-11-01       Impact factor: 47.728

10.  Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils.

Authors:  K Takeda; B E Clausen; T Kaisho; T Tsujimura; N Terada; I Förster; S Akira
Journal:  Immunity       Date:  1999-01       Impact factor: 31.745

View more
  457 in total

1.  The neurotensin receptor-1 promotes tumor development in a sporadic but not an inflammation-associated mouse model of colon cancer.

Authors:  James M Bugni; Leina Al- Rabadi; Kevin Jubbal; Iordanis Karagiannides; Gregory Lawson; Charalabos Pothoulakis
Journal:  Int J Cancer       Date:  2011-11-17       Impact factor: 7.396

2.  Elevated inflammatory response in caveolin-1-deficient mice with Pseudomonas aeruginosa infection is mediated by STAT3 protein and nuclear factor kappaB (NF-kappaB).

Authors:  Kefei Yuan; Canhua Huang; John Fox; Madeleine Gaid; Andrew Weaver; Guoping Li; Brij B Singh; Hongwei Gao; Min Wu
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

3.  Breaking the NF-κB and STAT3 alliance inhibits inflammation and pancreatic tumorigenesis.

Authors:  Young-Joon Surh; Ann M Bode; Zigang Dong
Journal:  Cancer Prev Res (Phila)       Date:  2010-10-26

4.  Dietary compounds as potent inhibitors of the signal transducers and activators of transcription (STAT) 3 regulatory network.

Authors:  Anne Trécul; Franck Morceau; Mario Dicato; Marc Diederich
Journal:  Genes Nutr       Date:  2012-01-25       Impact factor: 5.523

5.  Dysfunction of the cochlea contributing to hearing loss in acoustic neuromas: an underappreciated entity.

Authors:  Christof Roosli; Fred H Linthicum; Sebahattin Cureoglu; Saumil N Merchant
Journal:  Otol Neurotol       Date:  2012-04       Impact factor: 2.311

Review 6.  Therapeutic dormancy to delay postsurgical glioma recurrence: the past, present and promise of focal hypothermia.

Authors:  Didier Wion
Journal:  J Neurooncol       Date:  2017-05-17       Impact factor: 4.130

Review 7.  Obesity, energy balance, and cancer: new opportunities for prevention.

Authors:  Stephen D Hursting; John Digiovanni; Andrew J Dannenberg; Maria Azrad; Derek Leroith; Wendy Demark-Wahnefried; Madhuri Kakarala; Angela Brodie; Nathan A Berger
Journal:  Cancer Prev Res (Phila)       Date:  2012-10-03

8.  Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.

Authors:  Chi Young Ok; Ling Li; Zijun Y Xu-Monette; Carlo Visco; Alexander Tzankov; Ganiraju C Manyam; Santiago Montes-Moreno; Karen Dybkaer; Karen Dybaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Jiayu Chen; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; John P Farnen; Michael B Møller; Carlo E Bueso-Ramos; Roberto N Miranda; Jane N Winter; Miguel A Piris; L Jeffrey Medeiros; Ken H Young
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

9.  Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer.

Authors:  Jingjing Gong; Jianping Xie; Roble Bedolla; Paul Rivas; Divya Chakravarthy; James W Freeman; Robert Reddick; Scott Kopetz; Amanda Peterson; Huamin Wang; Susan M Fischer; Addanki P Kumar
Journal:  Clin Cancer Res       Date:  2014-02-11       Impact factor: 12.531

Review 10.  Common and Novel Markers for Measuring Inflammation and Oxidative Stress Ex Vivo in Research and Clinical Practice-Which to Use Regarding Disease Outcomes?

Authors:  Alain Menzel; Hanen Samouda; Francois Dohet; Suva Loap; Mohammed S Ellulu; Torsten Bohn
Journal:  Antioxidants (Basel)       Date:  2021-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.